Autobahn Speeds Lead Drug Into Phase II With $100m In Fresh Cash

Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.